Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CMPX 
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: CMPX (5-star) is a STRONG-BUY. BUY since 64 days. Simulated Profits (48.73%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.62
1 Year Target Price $12.62
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 335.45% | Avg. Invested days 43 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 914.21M USD | Price to earnings Ratio - | 1Y Target Price 12.62 |
Price to earnings Ratio - | 1Y Target Price 12.62 | ||
Volume (30-day avg) 9 | Beta 1.25 | 52 Weeks Range 1.33 - 5.86 | Updated Date 12/10/2025 |
52 Weeks Range 1.33 - 5.86 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.47% | Return on Equity (TTM) -37.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 704183204 | Price to Sales(TTM) 439.25 |
Enterprise Value 704183204 | Price to Sales(TTM) 439.25 | ||
Enterprise Value to Revenue 109.28 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 177862102 | Shares Floating 107997868 |
Shares Outstanding 177862102 | Shares Floating 107997868 | ||
Percent Insiders 10.99 | Percent Institutions 83.31 |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics, Inc. was founded in 2014 and is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies to treat patients with cancer and autoimmune diseases. The company has achieved significant milestones including the progression of its lead candidate, CTX-8371, into clinical trials and establishing key partnerships.
Core Business Areas
- Oncology Immunotherapies: Development of novel antibody-based therapeutics designed to modulate the immune system to fight cancer. This includes targeting specific checkpoints and pathways that are dysregulated in various tumor types.
- Autoimmune Disease Therapeutics: Exploration of immunotherapies for autoimmune conditions, aiming to rebalance the immune response and reduce inflammation and tissue damage.
Leadership and Structure
Compass Therapeutics is led by a management team with experience in drug discovery, development, and commercialization. The company operates under a typical biotech organizational structure, with departments for research and development, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- Competitors: Bristol Myers Squibb (Opdualag - Nivolumab/Relatlimab),Merck & Co. (Keytruda - Pembrolizumab),Roche (Tecentriq - Atezolizumab)
- Description: A novel bispecific antibody designed to simultaneously block the PD-1 and LAG-3 immune checkpoints. This dual blockade aims to overcome resistance to single-agent checkpoint inhibitors and enhance anti-tumor immune responses. CTP is currently investigating CTX-8371 in Phase 1 clinical trials for various solid tumors.
- Market Share Data: N/A (Currently in clinical development)
- Product Name 1: CTX-8371 (PD-1/LAG-3 bispecific antibody)
Market Dynamics
Industry Overview
The oncology immunotherapy market is a rapidly growing and highly competitive sector driven by advancements in understanding cancer biology and the immune system. Significant investment is being poured into developing novel therapies, including checkpoint inhibitors, bispecific antibodies, and cell therapies.
Positioning
Compass Therapeutics is positioning itself as a developer of next-generation immunotherapies that aim to improve efficacy and overcome resistance mechanisms seen with existing treatments. Their focus on bispecific antibodies and novel target combinations is a key aspect of their competitive strategy.
Total Addressable Market (TAM)
The TAM for oncology immunotherapies is in the tens of billions of dollars globally and is projected to continue growing. Compass Therapeutics is positioned to capture a share of this market by developing therapies for a broad range of cancers and potentially autoimmune diseases.
Upturn SWOT Analysis
Strengths
- Novel bispecific antibody technology (CTX-8371).
- Experienced management team.
- Focus on overcoming resistance to existing immunotherapies.
- Pipeline with potential for multiple indications.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Significant capital requirements for drug development.
- Limited brand recognition compared to established players.
Opportunities
- Growing demand for more effective cancer treatments.
- Potential for strategic partnerships and collaborations.
- Expansion into autoimmune disease indications.
- Advancements in diagnostic tools to identify patient populations likely to respond.
Threats
- Intense competition in the immunotherapy space.
- High failure rates in clinical trials.
- Regulatory hurdles and long approval timelines.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Roche (RHHBY)
- Pfizer (PFE)
- AstraZeneca (AZN)
Competitive Landscape
Compass Therapeutics faces a highly competitive landscape dominated by large pharmaceutical companies with extensive resources and established pipelines. Its competitive advantage lies in its innovative approach to bispecific antibodies and its focus on targets that address unmet needs in immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: The company's growth trajectory has been characterized by advancements in its drug discovery and development programs, including the progression of CTX-8371 into clinical trials.
Future Projections: Future growth projections are highly dependent on the success of its ongoing clinical trials and potential regulatory approvals. Analyst estimates would be contingent on these factors.
Recent Initiatives: Recent initiatives include the advancement of CTX-8371 into Phase 1 clinical trials, ongoing preclinical research into other novel targets, and potentially strategic collaborations.
Summary
Compass Therapeutics Inc. is a promising clinical-stage biopharmaceutical company with a novel bispecific antibody, CTX-8371, showing potential in cancer immunotherapy. Its strengths lie in its innovative technology and experienced team. However, as a clinical-stage entity, it faces significant risks related to trial success and substantial capital needs. The company must navigate a highly competitive market and secure further funding to advance its pipeline to achieve commercial success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials.
- SEC filings (10-K, 10-Q).
- Industry analysis reports.
- Financial data aggregators.
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial professional and conducting independent research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody for angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.